Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts for its lead complement inhibitor program and provide updated timing on ...
Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...
Everyday Health on MSN
The CIDP mindset: How to manage ‘relapse anxiety’ and medical trauma
Living with chronic inflammatory demyelinating polyneuropathy (CIDP) means managing more than physical symptoms. Learn how to handle ‘relapse anxiety’ and differentiate between normal nerve sensations ...
Olympian Michael Klim forged his reputation on strength and athleticism. But after being blindsided by an incurable ...
Everyday Health on MSN
The 'energy budget': Master the spoon theory for chronic fatigue in CIDP
Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the ...
1d
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...
Rare diseases affect only a small number of people yet have become an attractive target for ASX healthcare companies. ... Read More The post ASX healthcare players focusing on rare diseases as ...
In a poignant journey of resilience, Olympian Michael Klim faced a life-altering challenge when his athletic prowess was stripped away by chronic inflammatory demyelinating polyneuropathy (CIDP). This ...
A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. | A ...
Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire.
A Laikipia apparel manufacturer and I were reflecting on the pathways of moving from ideas to winning an election, to implementation and results.We noted how ideas must be synthesised into a governor ...
IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results